

1. Record Nr.	UNINA9910829127303321
Titolo	Lupus : symptoms, treatment and potential complications // Thiago Devesa Marquez and Davi Urgeiro Neto, editors
Pubbl/distr/stampa	Happauge, NY, : Nova Science Publishers, c2012
ISBN	1-62081-098-0
Edizione	[1st ed.]
Descrizione fisica	1 online resource (221 p.)
Altri autori (Persone)	MarquezThiago Devesa NetoDavi Urgeiro
Disciplina	616.7/72
Soggetti	Systemic lupus erythematosus Autoimmune diseases
Lingua di pubblicazione	Inglese
Formato	Materiale a stampa
Livello bibliografico	Monografia
Note generali	Description based upon print version of record.
Nota di bibliografia	Includes bibliographical references and index.
Nota di contenuto	Intro -- LUPUS: SYMPTOMS, TREATMENT AND POTENTIAL COMPLICATIONS -- LUPUS: SYMPTOMS, TREATMENT AND POTENTIAL COMPLICATIONS -- Library of Congress Cataloging-in-Publication Data -- Contents -- Preface -- Chapter I: Lupus Erythematosus: A Comprehensive Review -- Abstract -- Abbreviations -- Defining Lupus -- Lupus Incidence and Prevalence -- Causes of Lupus -- Diagnosing Lupus -- Autoantibodies in Lupus -- Lupus Blood Tests -- Urine Testing -- Other Tests -- Pregnancy and Contraception for Women with Lupus -- Current Research in Lupus -- Genetics in Lupus -- Biomarkers -- The Disease Process -- Lupus and the Skin, Hair and Mucosae -- Lupus and the Sun -- Lupus and the Musculoskeletal System -- Podiatric Care in Lupus -- Lupus and the Mucosae -- Mixed Connective Tissue Disease, or Overlap Syndrome -- Differential Diagnoses of Lupus -- Coping with Lupus among Family and Friends -- Treatment -- NSAIDs -- Antimalarials -- Corticosteroids -- Immunosuppressives -- BlyS-Specific Inhibitors -- Other Lupus Therapies -- Alternative and Complementary Therapies -- References -- Chapter II: Autoantibody-Producing B Cells and B Cell Therapy in Systemic Lupus Erythematosus - Possible New Targets of Novel Subsets of RP105-Negative B Cells -- Abstract -- Introduction -- Section 1. B Cell Biology in SLE -- Section 2. Therapies of Targeting B Cells in SLE -- Conclusion -- Reference -- Chapter III: Neuropsychiatric Manifestations

in Systemic Lupus Erythematosus -- Abstract -- Introduction -- Classification Criteria -- NPSLE Epidemiology -- Clinical Relevance -- Risk Factors for NPSLE -- Pathophysiology -- Diagnosis -- Clinical and Laboratory Investigation -- Therapeutic Strategies in NPSLE -- Conclusion -- Acknowledgments -- References -- Chapter IV: Treatment in Systemic Lupus Erythematosus -- Abstract -- Introduction -- Conventional Therapies -- B-Cell Targeting. T-Cell Targeting and Co-Stimulatory Blockade -- Anticytokines Therapy -- Complement Inhibition -- Conclusion -- Acknowledgments -- References -- Chapter V: Hematologic Manifestations of Systemic Lupus Erythematosus -- Anemia -- Leukopenia -- Lymphopenia -- Neutropenia -- Thrombocytopenia -- Bone Marrow as a Target Organ in SLE -- Hematological Manifestations, SLE Subsets and Prognosis -- References -- Chapter VI: Interleukin-21 in Systemic Lupus Erythematosus: Pathogenic Relevance and Therapeutic Applications -- Abstract -- Introduction: Overview on Systemic Lupus Erythematosus -- Multiple Roles for B Cells in SLE -- IL-21 Is a Critical Regulator of B Cell Responses -- IL-21 and SLE -- Treatment of Spontaneous Lupus Mice Using Agents Able to Block IL-21/IL-21R Signaling -- Conclusion -- References -- Chapter VII: Metabolic Syndrome and Inflammatory Cytokines in Systemic Lupus Erythematosus -- Abstract -- Introduction -- CVD in SLE -- Traditional Risk Factors -- Non-Traditional Risk Factors -- CVD Features and Cytokines Involved on SLE -- Relationship between SLE Treatment in Patients with MetS -- What Is the Best Treatment to MetS in SLE Patients? -- Conclusion and Perspective Future -- Acknowledgments -- References -- Chapter VIII: Pulmonary Hypertension in Systemic Lupus Erythematosus -- Definition -- Classification -- Pulmonary Manifestations in SLE -- Epidemiology -- Pathogenesis -- Clinical Manifestations -- Diagnostic Methods -- Autoantibodies -- Pregnancy -- Treatment -- Immunosuppressive Therapy -- Sildenafil -- Prostanoids -- Endothelin Receptor Antagonists -- Transplantation -- Prognosis -- Conclusion -- References -- Chapter IX: Dual Roles for Antibodies in Lupus Nephritis -- Abstract -- The Origins of Pathogenic Antibodies in Autoimmunity -- Pathogenic Antibodies in Lupus -- Anti-DsDNA IgM Protects against Lupus Nephritis -- Conclusion. References -- Chapter X: Treatment of Systemic Lupus Erythematosus with Intravenous Immunoglobulins: Case Studies -- Abstract -- Introduction -- Case Study 1 -- Case Study 2 -- Discussion -- Conclusion -- References -- Chapter XI: APRV (Airway Pressure-Release Ventilation) as Supportive Management for Diffuse Alveolar Hemorrhage with Systemic Lupus Erythematosus -- Abstract -- Introduction -- APRV and DAH -- Cases -- References -- Index.

---